Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market 2017 Global Analysis, Opportunities and Forecast To 2020

Global attention deficit hyperactivity disorder (ADHD) therapeutics market is expected to reach USD 12.43 billion by 2020 from USD 8.08 billion in 2015, growing at a CAGR of 9.00% during the forecast period 2015-2020

Pune, India - March 21, 2017 /MarketersMedia/ —

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Industry

Description

Global attention deficit hyperactivity disorder (ADHD) therapeutics market is expected to reach USD 12.43 billion by 2020 from USD 8.08 billion in 2015, growing at a CAGR of 9.00% during the forecast period 2015-2020. Attention deficit hyperactivity disorder (ADHD), is one of the most common neurological/psychiatric disorders among children and adolescents. ADHD is commonly observed in children (<12 years age) as compared to adolescents. ADHD is also described as hyperkinetic disorder/ attention deficit disorder or neuropsychiatric disorder. The exact cause for the ADHD is not clear but, expected to be resulted due to genetic factors and environmental influences. ADHD results in improper functioning of nervous system that led to attention deficit and hyperactivity/impulsiveness condition. ADHD is characterized by certain symptoms include easy distraction & striving to maintain focus on one task, unable to remember things, impatience, and being continuously in motion, among others. The symptoms of attention deficit hyperactivity disorder (ADHD) are controlled by different modalities such as medication (stimulants-amphetamines; non-stimulants-atomoxetine), psychotherapy (behavior therapy, cognitive behavioral therapy), and education/training (parent management training, family training).

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/635472-attention-deficit-hyperactivity-disorder-2015-to-2020

Increasing advancements in medical field, growing number of researches in neurosciences, rising awareness about mental illness among people, and increasing focus of biotechnology & pharmaceutical companies to develop the innovative therapeutics for ADHD are driving the growth of global attention deficit hyperactivity disorder therapeutics market. However, high cost of the ADHD medications, improper reimbursement policies, and side effects related to ADHD medications (such as insomnia, anorexia, dizziness, headaches, and mood changes) are restraining the growth of global attention deficit hyperactivity disorder therapeutics market.

Global attention deficit hyperactivity disorder (ADHD) therapeutics market is segmented based on medication, psychotherapy, and education or training. Medication involves stimulants and non-stimulants. Medication by stimulants comprises of amphetamines, methylphenidate, dextroamphetamine, and dexmethylphenidate, whereas medication by non-stimulants comprises of atomoxetine, bupropion, and guanfacine. Psychotherapy involves behavior therapy, cognitive behavioral therapy, interpersonal psychotherapy, and family therapy. Education or training involves parent management training, social skills training, and school-based interventions.

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=635472
On the basis of geographical region the global attention deficit hyperactivity disorder (ADHD) therapeutics market is segmented as North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. North America commanded the highest share of 36.0% of the global attention deficit hyperactivity disorder (ADHD) therapeutics market in 2015, whereas Asia-Pacific is estimated to grow at the highest CAGR of 12.30% during the forecast period 2015-2020.

The key players in global attention deficit hyperactivity disorder (ADHD) therapeutics market such as,

Shire plc (Ireland), Neos Therapeutics, Inc. (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Alcobra Ltd. (Israel), Supernus Pharmaceuticals, Inc. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson (U.S.), and Curemark, LLC. (U.S.).

Report Detail’s@ https://www.wiseguyreports.com/reports/635472-attention-deficit-hyperactivity-disorder-2015-to-2020

Table of Content

Introduction
1.1 Market Definition

1.2 Study Deliverables

1.3 Base Currency, Base Year and Forecast Periods

1.4 General Study Assumptions

2. Research Methodology
2.1 Introduction

2.2 Research Phases

2.2.1 Secondary Research

2.2.2 Primary Research

2.2.3 Econometric Modelling

2.2.4 Expert Validation

2.3 Analysis Design

2.4 Study Timeline

3. Overview
3.1 Executive Summary

3.2 Key Inferences

3.3 New Developments

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers

4.2 Market Restraints

4.3 Key Challenges

4.4 Current Opportunities in the Market

Continued...

Contact Us: [email protected] Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

Contact Info:
Name: NORAH TRENT
Email: [email protected]
Organization: WISE GUY RESEARCH CONSULTANTS PVT LTD
Address: Pune -40027, Maharashtra, India
Phone: +91 841 198 5042

Source URL: http://marketersmedia.com/attention-deficit-hyperactivity-disorder-adhd-therapeutics-market-2017-global-analysis-opportunities-and-forecast-to-2020/169771

For more information, please visit https://www.wiseguyreports.com/sample-request/635472-attention-deficit-hyperactivity-disorder-2015-to-2020

Source: MarketersMedia

Release ID: 169771